Characteristics of respiratory dysfunction in patients with myasthenia gravis based on a comprehensive functional study
Abstract. Myasthenia gravis (MG) is an autoimmune disease in which respiratory muscle weakness is manifesting itself as a life-threatening condition. However, data on comprehensive assessment of respiratory function using modern methods are rare. The aim: to study the prevalence and nature of respiratory dysfunction in patients with MG. Material and methods. A cross-sectional study included 66 patients (21 male and 45 females) with MG. The mean age of the participants was 57.0 ± 17.9 years, and the median disease duration was 8 [4; 12] years. Patients underwent a 6-minute walk test (SMWT), mMRC dyspnea estimation, spirometry, body plethysmography, pulse oscillometry, measurement of maximal inspiratory and expiratory pressures (MIP, MEP), and diffusing capacity of lungs (DLCO). Results. The most common disorder was a decrease in respiratory muscle strength: MIP <80% in 65.6%, MEP <80% – 50.8% in the studied patients with MG. Restrictive disorders according to spirometry data (forced vital capacity <80%) were detected in 22.7%, according to body plethysmography data (total lung capacity <80%) – in 17.7% of patients, obstructive disorders (the ratio of forced expiratory volume in 1 second to forced vital capacity <70%) – in 18.2% of participants. Hyperinflation (the ratio of residual volume to total lung capacity >40%) was noted in 24.2%, a decrease in inspiratory capacity <80% – in 41.9% of patients. Among patients, in whom with pulmonary diffusion capacity assessment was performed (n = 7), decreased DLCO and alveolar volume were observed in 85% of cases, and decreased KCO (the ratio of DLCO to alveolar volume) in 28.6%. According to pulse oscillometry data (n = 24), increased respiratory resistance at 5 Hz (R5 >120%) was recorded in 50% of patients, and an increase in resonance frequency (Fres >100%) was observed in 58.3% of participants. Decreased exercise tolerance (SMWT <500 m) was observed in 42.4%, clinically significant dyspnea (mMRC ≥2) in 25.7%, significant symptoms according to MG-ADL (≥6 points) in 34.8% of patients. Conclusion. The study results demonstrate a high frequency of functional disorders in patients with myasthenia gravis. Obtained data substantiate the need to integrate pulmonary screening into the standard care of patients with neuromuscular disorders.G.L. Ignatova, V.N. Antonov, M.I. Karpova, S.B. Stepanova, O.V. Rodionova, V.S. Belogorokhov, D.K. Romanova, A.S. Kashigina
Keywords
myasthenia gravis
pulmonary function
body plethysmography
pulse oscillometry
assessment of lung diffusion capacity
References
1. García Estevez DA, Pardo Fernandez J. Myasthenia gravis. Update on diagnosis and therapy. Med Clin (Barc). 2023;161(3):119–27.
PMID: 37248131. https://doi.org/10.1016/j.medcli.2023.04.006
2. Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8–19.
PMID: 37114503. https://doi.org/10.1002/mus.27832
3. Gilhus NE, Verschuuren JJ. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–36.
PMID: 26376969. https://doi.org/10.1016/S1474-4422(15)00145-3
4. (Liang Y, Yang WJ, Sun DY, Li N, Wang Z. Epidemiological survey of myasthenia gravis in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(6):647–52 (In Chinese)).
PMID: 31238611. https://doi.org/10.3760/cma.j.issn.0254-6450.2019.06.007
5. Alcantara M, Barnett-Tapia C, Bril V, Mannan S, Shabanpour J, Riaz S et al. Office-based respiratory assessment in patients with generalized myasthenia gravis. Neuromuscul Disord. 2024;34(5):105–11.
PMID: 38776756. https://doi.org/10.1016/j.nmd.2024.05.005
6. Keenan SP, Alexander D, Road JD, Ryan CF, Oger J, Wilcox PG. Ventilatory muscle strength and endurance in myasthenia gravis. Eur Respir J. 1995;8(7):1130–35.
PMID: 7589397. https://doi.org/10.1183/09031936.95.08071130
7. Iliaz S, Yunisova G, Cakmak OO, Celebi O, Bulus E, Duman A et al. The clinical use of impulse oscillometry in neuromuscular diseases. Respir Med. 2022;200:106931.
PMID: 35858508. https://doi.org/10.1016/j.rmed.2022.106931
About the Authors
Galina L. Ignatova, MD, Dr. Sci. (Medicine), head of the Department of therapy of the Institute of continuing professional education, South Ural State Medical University, Chelyabinsk, Russian Federation.E-mail: iglign@mail.ru
ORCID: https://orcid.org/0000-0002-0877-6554. eLibrary SPIN: 3582-5784. Scopus ID: 8899447500
Vladimir N. Antonov, MD, Dr. Sci. (Medicine), professor of the Department of therapy of the Institute of continuing professional education, South Ural State Medical University, Chelyabinsk, Russian Federation.
E-mail: ant-vn@yandex.ru
ORCID: https://orcid.org/0000-0002-3531-3491. eLibrary SPIN 5660-2160. Scopus ID: 56638963000
Maria I. Karpova, MD, Dr. Sci. (Medicine), head of the Department of nervous system diseases, South Ural State Medical University, Chelyabinsk, Russian Federation.
E-mail: kmi_2008@mail.ru
ORCID: https://orcid.org/0000-0001-5848-7235. eLibrary SPIN: 2177-2908. Scopus ID: 56299533100
Svetlana B. Stepanova, MD, PhD (Medicine), associate professor of the Department of nervous system diseases, South Ural State Medical University, Chelyabinsk, Russian Federation.
E-mail: sveta_step@inbox.ru
ORCID: https://orcid.org/0000-0002-3484-6165. eLibrary SPIN: 7724-5024. Scopus ID: 55883722500
Olga V. Rodionova, MD, PhD (Medicine), associate professor of the Department of therapy of the Institute of continuing professional education, South Ural State Medical University, Chelyabinsk, Russian Federation.
E-mail: olgalim0505@mail.ru
ORCID: https://orcid.org/0000-0002-0570-1135. eLibrary SPIN 9783-2231. Scopus ID: 5663904700
Veniamin S. Belogorokhov, MD, senior laboratory assistant at the Institute of pulmonology, South Ural State Medical University, Chelyabinsk, Russian Federation.
E-mail: benjaminbelogorohov@yandex.ru
ORCID: https://orcid.org/0009-0007-7414-3804. eLibrary SPIN 7879-1759. Scopus ID: 59374200200
Darya K. Romanova, MD, resident of the Department of nervous system diseases, South Ural State Medical University, Chelyabinsk, Russian Federation.
E-mail: romdarkon0908@gmail.com
ORCID: https://orcid.org/0009-0003-0025-342X
Anna S. Kashigina, MD, assistant at the Department of nervous system diseases, South Ural State Medical University, Chelyabinsk, Russian Federation.
E-mail: annnkashigina@gmail.com
ORCID: https://orcid.org/0009-0009-6147-1483
Similar Articles
